# Nexo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nexo-therapeutics

- Industry: Biotechnology
- Headquarters: Littleton, US
- Website: www.nexotx.com
- Total disclosed funding: $30M
- Latest round: Series A (Nov 15, 2022)
- Investors on record: 3

## About

Based in Colorado, US, and founded in 2022 by its CEO, Andrew Phillips, and co-founders Michael Kim, John Athanasopoulos, and Rhamy Zeid, Nexo Therapeutics, Inc. operates as a biotechnology company that is dedicated to developing drugs to target some cancer proteins. In July 2023, Nexo Therapeutics, Inc. raised USD 60 million in series A funding led by Versant Ventures, with participation from New Enterprise Associates and Cormorant Asset Management. 
 
Nexo Therapeutics, Inc. develops cutting-edge drugs that directly address elusive proteins associated with various types of cancer. Its CODON (Covalent Discovery and Optimization) platform combines chemical diversity and covalent chemistry within a scalable framework of biochemical and in-cell proteomics. 

The company plans to use the series A funding to uncover a pipeline of cancer medicines directed against formerly impenetrable targets.

## Funding rounds

- Series A, Nov 15, 2022, $30M — New Enterprise Associates, Versant Ventures, Cormorant Asset Management

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A